Current treatment landscape for obesity in Singapore
The rising prevalence of obesity in Singapore is a harbinger for a corresponding increase in obesity-related complications such as type 2 diabetes mellitus (T2DM) and coronary heart disease. Obesity is a complex disease driven by multiple factors, and hence, treatment cannot follow a ‘one-size-fits-...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer – Medknow Publications
2023-03-01
|
| Series: | Singapore Medical Journal |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/singaporemedj.SMJ-2022-216 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823861493171486720 |
|---|---|
| author | Phong Ching Lee Chin Hong Lim Ravishankar Asokkumar Marvin Wei Jie Chua |
| author_facet | Phong Ching Lee Chin Hong Lim Ravishankar Asokkumar Marvin Wei Jie Chua |
| author_sort | Phong Ching Lee |
| collection | DOAJ |
| description | The rising prevalence of obesity in Singapore is a harbinger for a corresponding increase in obesity-related complications such as type 2 diabetes mellitus (T2DM) and coronary heart disease. Obesity is a complex disease driven by multiple factors, and hence, treatment cannot follow a ‘one-size-fits-all’ approach. Lifestyle modifications involving dietary interventions, physical activity and behavioural changes remain the cornerstone of obesity management. However, similar to other chronic diseases such as T2DM and hypertension, lifestyle modifications are often insufficient on their own, hence the importance of other treatment modalities including pharmacotherapy, endoscopic bariatric therapy and metabolic–bariatric surgery. Weight loss medications currently approved in Singapore include phentermine, orlistat, liraglutide and naltrexone–bupropion. In recent years, endoscopic bariatric therapies have evolved as an effective, minimally invasive and durable therapeutic option for obesity. Metabolic–bariatric surgery remains the most effective and durable treatment for patients with severe obesity, with an average weight loss of 25%–30% after one year. |
| format | Article |
| id | doaj-art-af42ba7eb9ef4e188f7a41add6b8d592 |
| institution | Kabale University |
| issn | 0037-5675 2737-5935 |
| language | English |
| publishDate | 2023-03-01 |
| publisher | Wolters Kluwer – Medknow Publications |
| record_format | Article |
| series | Singapore Medical Journal |
| spelling | doaj-art-af42ba7eb9ef4e188f7a41add6b8d5922025-02-09T13:45:41ZengWolters Kluwer – Medknow PublicationsSingapore Medical Journal0037-56752737-59352023-03-0164317218110.4103/singaporemedj.SMJ-2022-216Current treatment landscape for obesity in SingaporePhong Ching LeeChin Hong LimRavishankar AsokkumarMarvin Wei Jie ChuaThe rising prevalence of obesity in Singapore is a harbinger for a corresponding increase in obesity-related complications such as type 2 diabetes mellitus (T2DM) and coronary heart disease. Obesity is a complex disease driven by multiple factors, and hence, treatment cannot follow a ‘one-size-fits-all’ approach. Lifestyle modifications involving dietary interventions, physical activity and behavioural changes remain the cornerstone of obesity management. However, similar to other chronic diseases such as T2DM and hypertension, lifestyle modifications are often insufficient on their own, hence the importance of other treatment modalities including pharmacotherapy, endoscopic bariatric therapy and metabolic–bariatric surgery. Weight loss medications currently approved in Singapore include phentermine, orlistat, liraglutide and naltrexone–bupropion. In recent years, endoscopic bariatric therapies have evolved as an effective, minimally invasive and durable therapeutic option for obesity. Metabolic–bariatric surgery remains the most effective and durable treatment for patients with severe obesity, with an average weight loss of 25%–30% after one year.https://journals.lww.com/10.4103/singaporemedj.SMJ-2022-216endoscopic bariatric therapylifestyle modificationmetabolic–bariatric surgerytreatment of obesityweight loss pharmacotherapy |
| spellingShingle | Phong Ching Lee Chin Hong Lim Ravishankar Asokkumar Marvin Wei Jie Chua Current treatment landscape for obesity in Singapore Singapore Medical Journal endoscopic bariatric therapy lifestyle modification metabolic–bariatric surgery treatment of obesity weight loss pharmacotherapy |
| title | Current treatment landscape for obesity in Singapore |
| title_full | Current treatment landscape for obesity in Singapore |
| title_fullStr | Current treatment landscape for obesity in Singapore |
| title_full_unstemmed | Current treatment landscape for obesity in Singapore |
| title_short | Current treatment landscape for obesity in Singapore |
| title_sort | current treatment landscape for obesity in singapore |
| topic | endoscopic bariatric therapy lifestyle modification metabolic–bariatric surgery treatment of obesity weight loss pharmacotherapy |
| url | https://journals.lww.com/10.4103/singaporemedj.SMJ-2022-216 |
| work_keys_str_mv | AT phongchinglee currenttreatmentlandscapeforobesityinsingapore AT chinhonglim currenttreatmentlandscapeforobesityinsingapore AT ravishankarasokkumar currenttreatmentlandscapeforobesityinsingapore AT marvinweijiechua currenttreatmentlandscapeforobesityinsingapore |